Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
PLANCK (PLANCK) fluctuates by 40.7% in 24 hours: BinanceAlpha delisting announcement triggers surge in trading volume

PLANCK (PLANCK) fluctuates by 40.7% in 24 hours: BinanceAlpha delisting announcement triggers surge in trading volume

Bitget PulseBitget Pulse2026/03/14 16:02
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, PLANCK price rebounded from a low of $0.00091 to a high of $0.00128, currently at $0.00109, with a fluctuation range of 40.7%. 24-hour trading volume is approximately $1.219 million, significantly enlarged compared to the previous day.

Brief Analysis of Abnormal Movements

- The Binance Alpha delisting announcement directly triggered a surge in trading volume and sharp price fluctuations. After the announcement, the price rebounded from a low of $0.00101 to a high of $0.00157.

- The project team (including CEO @HamstraDiam and CTO @rohantalwadia) remained silent after the announcement, with developer account updates stalled.

Market Views and Outlook

Mainstream sentiment in the community is negative, with discussions on X platform focused on “red flags” and potential project abandonment risks. Multiple users warn against buying in and view the team's silence as a “rug pull” signal; analysts see no optimistic forecasts, short-term volatility may persist and remain under pressure due to the delisting impact.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.
0
1

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales